Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2024 Annual Meeting | C5 - Anti-amyloid Therapy Boot Camp

Saturday 04/13/24
09:00 AM - 04:30 PM MDT Add To Calendar
Colorado Convention Center | Four Seasons 2/3
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Full-Day Course
Jonathan Graff-Radford, MD, FAAN
Aging, Dementia, Cognitive, and Behavioral Neurology
Participants should be able to appraise major findings from recent clinical trials of anti-amyloid monoclonal antibody therapies in Alzheimer's disease; understand imaging and fluid biomarkers relevant for treatment eligibility and monitoring; identify proposed clinical criteria for appropriate use of anti-amyloid therapies in clinical practice; summarize mechanisms, risk factors, and safety monitoring for amyloid-related imaging abnormalities; and assess practice-level adaptations needed for emerging AD therapies.
 
This program is supported in part by educational grants from Lilly and Eisai Inc.
7.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Advanced
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Business Administrator
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
09:00 AM - 09:20 AM MDT Speaker Background: Comparing Donanemab and Lecanemab and Aducanumab
Gil Dan Rabinovici, MD, FAAN
09:20 AM - 09:40 AM MDT Speaker Patient Selection, Inclusion/Exclusion, and Appropriate Use Criteria
Judith L. Heidebrink, MD
09:40 AM - 10:00 AM MDT Speaker Making a Clinical Diagnosis of MCI or Mild Dementia
David A. Wolk, MD, FAAN
10:00 AM - 10:10 AM MDT Break Break
10:10 AM - 10:40 AM MDT Speaker Interpreting Fluid Biomarkers (CSF and Plasma)
Melissa Yu, MD, FAAN
10:40 AM - 11:10 AM MDT Speaker Amyloid PET and Possible Use of Tau PET
Joseph C. Masdeu, MD, PhD, FAAN
11:10 AM - 11:40 AM MDT Speaker APOE Disclosure and Shared Decision-making Approach
Vijay K. Ramanan, MD, PhD
11:40 AM - 12:00 PM MDT Q&A Questions & Answers
12:00 PM - 01:00 PM MDT Break Lunch Break
01:00 PM - 01:30 PM MDT Speaker Complications, including ARIA Frequency and Management
Joseph C. Masdeu, MD, PhD, FAAN
01:30 PM - 02:00 PM MDT Speaker How to Detect ARIA and Partner with Radiology for MRI Protocols
Petrice Mostardi Cogswell, MD,PhD
02:00 PM - 02:20 PM MDT Speaker Logistical Considerations (Non-imaging)—Initial Evaluations, Infusions, Safety Monitoring, tPA
Vijay K. Ramanan, MD, PhD
02:20 PM - 02:40 PM MDT Speaker Registries
Melissa Yu, MD, FAAN
02:40 PM - 03:00 PM MDT Speaker Private Practice Perspective
David C. Weisman, MD
03:00 PM - 03:10 PM MDT Break Break
03:10 PM - 03:30 PM MDT Speaker Cases
Peter A. Ljubenkov, MD
03:30 PM - 04:00 PM MDT Q&A Questions & Answers
Faculty Disclosures
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai.
Gil Dan Rabinovici, MD, FAAN Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. The institution of Dr. Rabinovici has received research support from Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Vijay K. Ramanan, MD, PhD The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Petrice Mostardi Cogswell, MD,PhD Dr. Cogswell has nothing to disclose.
Peter A. Ljubenkov, MD Dr. Ljubenkov has nothing to disclose.
Joseph C. Masdeu, MD, PhD, FAAN Dr. Masdeu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Masdeu has received research support from NIH. The institution of Dr. Masdeu has received research support from Moody Foundation. The institution of Dr. Masdeu has received research support from Biogen. The institution of Dr. Masdeu has received research support from Eli Lilly. The institution of Dr. Masdeu has received research support from Eisai. The institution of Dr. Masdeu has received research support from Novartis. Dr. Masdeu has received publishing royalties from a publication relating to health care. Dr. Masdeu has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Nantz Nal Alzheimer Center with HOUSTON METHODIST NEUROLOGICAL INSTITUTE.
David C. Weisman, MD Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iqvia. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acumen. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly. The institution of Dr. Weisman has received research support from Eisai. The institution of Dr. Weisman has received research support from Biogen. The institution of Dr. Weisman has received research support from Roche. The institution of Dr. Weisman has received research support from Vivoryon. The institution of Dr. Weisman has received research support from Lilly. The institution of Dr. Weisman has received research support from Acumen. The institution of Dr. Weisman has received research support from Cerevel. The institution of Dr. Weisman has received research support from Sage. The institution of Dr. Weisman has received research support from Annovis. The institution of Dr. Weisman has received research support from Serono. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Temporary voting member with FDA.
David A. Wolk, MD, FAAN Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Functional Neuromodulation. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. The institution of Dr. Wolk has received research support from Biogen. Dr. Wolk has received publishing royalties from a publication relating to health care. Dr. Wolk has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Eli Lilly.
Melissa Yu, MD, FAAN An immediate family member of Dr. Yu has received personal compensation for serving as an employee of CVS/Aetna. The institution of Dr. Yu has received research support from Alzheimer's Association. The institution of Dr. Yu has received research support from Biogen. The institution of Dr. Yu has received research support from Eisai. The institution of Dr. Yu has received research support from Novo Nordisk. The institution of Dr. Yu has received research support from Suven. The institution of Dr. Yu has received research support from AriBio.
Judith L. Heidebrink, MD The institution of Dr. Heidebrink has received research support from Biohaven. The institution of Dr. Heidebrink has received research support from Eli Lilly. The institution of Dr. Heidebrink has received research support from Eisai. The institution of Dr. Heidebrink has received research support from NIH. The institution of Dr. Heidebrink has received research support from Alzheimer's Association. Dr. Heidebrink has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member for the IMPACT-AD Clinical Trials course with the University of Southern California (funded by NIA/Alzheimer's Association).